# of Displayed Technologies: 30 / 105

Applied Category Filter (Click To Remove): Therapeutics


Categories

Humanized SSTR2 mAb and ADC to target SSTR2+ tumors
TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment
The Liu Lab Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapi…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

Small Molecule USP30 Inhibitors for the Treatment and Prevention of Cardiomyopathy
TS-066773 — The Need Cardiomyopathy, a disease of the heart muscle, poses significant public health challenges due to its diverse causes, symptoms, and potential complications, including heart failure and arrhythmias. With cardiomyopathy often induced by drugs, such as anthracyclines used in chemotherapy, ther…
  • College: College of Medicine (COM)
  • Inventors: Sun, Nuo; Krigman, Judith; Yang, Mingchong; Zhang, Ruohan
  • Licensing Officer: Willson, Christopher

Advanced Dual-Layer Compositions for Enhanced Delivery and Stability of Biologically Active Agents
TS-066770 — The Need In the realm of human and mammalian health, delivering biologically active components that are sensitive to moisture or other environmental factors has posed a significant challenge. Traditional methods, such as encapsulation or use of desiccants, often fall short in ensuring stability and…
  • College: Office of Business and Finance
  • Inventors:
  • Licensing Officer: Dahlman, Jason "Jay"

Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…
  • College: College of Arts & Sciences
  • Inventors: Pei, Dehua
  • Licensing Officer: Dahlman, Jason "Jay"

Innovative Small Molecule Inhibitors for Effective Treatment and Prevention of Coronavirus Infections
TS-066750 — The ongoing COVID-19 pandemic, caused by the SARS-CoV-2 virus, has significantly impacted global health and economies. Despite vaccine efforts, issues such as vaccine hesitancy, delays in distribution, and emerging variants have highlighted the need for effective therapeutic interventions. These i…
  • College: College of Veterinary Medicine
  • Inventors: Sharma, Amit; Li, Pui-Kai "Tom"; Xing, Enming
  • Licensing Officer: Willson, Christopher

Innovative Solutions for Cell Viability and Targeted Delivery
TS-066100 — Research tool to transfect cells ex vivo using electroporation through electrospun core-shell fibers for research applications
The Need: Conventional electroporation methods often result in low cell viability due to heat generation, especially when working with primary cells. These methods also face challenges with non-specific transport of molecules, high vector integration rates leading to mutagenesis, and inefficacy in …
  • College: College of Engineering (COE)
  • Inventors: Gallego Perez, Daniel; Das, Devleena; Duarte Sanmiguel, Silvia; Higuita Castro, Natalia
  • Licensing Officer: Willson, Christopher

T-cells with Enhanced Ability to Respond to Exogenous Ligands
TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.
The Need As interest in cell-based therapies, particularly for cancer treatment, continues to rise, there’s a critical need for therapeutic cells capable of robust proliferation in vivo. Existing methods relying on exogenous cytokines like IL-2 face challenges due to dose-limiting toxicity an…
  • College: OSU Wexner Medical Center
  • Inventors: Rubinstein, Mark
  • Licensing Officer: Willson, Christopher

Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
  • College: OSU Wexner Medical Center
  • Inventors:
  • Licensing Officer: Willson, Christopher

Gene Therapy Approach for Treating Neuropathy
TS-065913 — Gene therapy strategies for treating peripheral neuropathy.
Peripheral neuropathy (PN) results in loss of innervation by the peripheral nerves in tissues such as skin, muscle, heart, and adipose tissue. It is a painful, debilitating disease, that is estimated to affect between 20 and 30 million Americans. The number of Americans affected by PN is likely muc…
  • College: College of Medicine (COM)
  • Inventors: Townsend, Kristy; Blaszkiewicz, Magdalena; Cao, Lei
  • Licensing Officer: Willson, Christopher

Method for sensitizing solid tumors to immunotherapy
TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …
  • College: College of Arts & Sciences
  • Inventors: Kural, Comert; Djakbarova, Umidahan
  • Licensing Officer: Wilburn, Adri

Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
  • College: College of Medicine (COM)
  • Inventors: Kerur, Nagaraj
  • Licensing Officer: Willson, Christopher

Treating Diabetes, Obesity, and Cardiovascular Disease by Reprogramming Skin
TS-065789 — Using tissue nano-transfection to reprogram skin cells to treat diabetes, obesity and/or cardiovascular health
The incidence of obesity and diabetes is skyrocketing, leading to chronic inflammatory conditions such as cardiovascular disease, autoimmune diseases, liver diseases, and cancer. Cardiovascular disease (CVD) is the leading cause of death across the US and worldwide and affects almost half of all ad…
  • College: College of Medicine (COM)
  • Inventors: Gallego Perez, Daniel; Higuita Castro, Natalia; Sen, Chandan
  • Licensing Officer: Willson, Christopher

Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes. The Need Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
  • College: College of Medicine (COM)
  • Inventors: Kaumaya, Pravin
  • Licensing Officer: Willson, Christopher

Precision RNA-PROTACs: Revolutionizing Therapeutic Targeting of Dysregulated Ribonucleoprotein Complexes
TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…
  • College: College of Arts & Sciences
  • Inventors: Bong, Dennis; Liang, Yufeng; Miao, Shiqin "Shiqin"; Strong, Rebekah
  • Licensing Officer: Panic, Ana

Enhancing Antibody Therapies Using a NOD2 Agonist
TS-065320 — Stimulating monocytes with a NOD2 agonist increases effectiveness of monoclonal antibody therapy.
An estimated 20,160 new cases of chronic lymphocytic leukemia (CLL) and 4,410 deaths were expected in 2022. Current therapies for CLL include the administration of a monoclonal antibody, such as rituximab, an anti-CD20 antibody, to promote clearance of malignant B cells. The Need Current therapies…
  • College: College of Medicine (COM)
  • Inventors: Tridandapani, Susheela; Butchar, Jonathan; Mehta, Payal; Merchand Reyes, Giovanna; Santhanam, Ramasamy
  • Licensing Officer: Willson, Christopher

Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
  • College: College of Medicine (COM)
  • Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
  • Licensing Officer: Willson, Christopher

Intracellular Targeting by Monoclonal Antibodies
TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
  • Licensing Officer: Dahlman, Jason "Jay"

Utilizing WT-IV-012 to improve immune checkpoint therapy in cancer treatment
TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…
  • College: College of Arts & Sciences
  • Inventors: Burd, Craig; Aguilar-Valenzuela, Renan; Burd, Christin
  • Licensing Officer: Panic, Ana

Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: OSU Wexner Medical Center
  • Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

CDP-choline a host-directed therapeutic for disease caused by SARS CoV-2 infection.
TS-064192 — The Need: The global impact of the SARS CoV-2 coronavirus has created an urgent need for innovative medical interventions to address the challenges posed by COVID-19. Despite the availability of vaccines, sub-optimal vaccine uptake and concerns about new virus variants necessitate additional medical…
  • College: College of Veterinary Medicine
  • Inventors: Davis, Ian; Schelhorn, Jean
  • Licensing Officer: Willson, Christopher

Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 — The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
  • Licensing Officer: Willson, Christopher

A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
  • College: College of Veterinary Medicine
  • Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
  • Licensing Officer: Willson, Christopher

Small molecules that suppress heat/pain perception
TS-064187 — The Need In the culinary and pharmaceutical realms, the need for a groundbreaking solution to modulate flavor and alleviate sensory perceptions is crucial. Businesses seek innovative ways to enhance consumer experiences by addressing pungency in foods and alleviating burn or pain sensations in phar…
  • College: College of Food, Agricultural, and Environmental Sciences (CFAES)
  • Inventors: Peterson, Devin; Borcherding, Joel
  • Licensing Officer: Dahlman, Jason "Jay"

Novel STK1-targeted small molecule "antibiotic resistance breaker" compounds
TS-063547 — Novel small molecule STK1 inhibitors that “break” the resistance of bacteria strains to antibiotics.
In today’s healthcare landscape, increasingly highly pathogenic and multidrug-resistant S. aureus (MDRSA) strains are replacing traditional methicillin-resistant S. aureus (MRSA) in both community and hospital settings. The Need The rise of these resilient multi-drug resistant bacteria has …
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Willson, Christopher

Protecting the vascular endothelial barrier – a novel approach to treating atrial fibrillation
TS-063433 — A new pharmacologic modality for treating AFib.
Atrial fibrillation (AF) is the most common form of irregular cardiac rhythm (arrhythmia), affecting approximately 3% of the US population. It is a significant risk factor for heart failure, ischemic stroke, and sudden cardiac death. The AF mortality rate is growing globally, and risk factors known …
  • College: College of Engineering (COE)
  • Inventors: Veeraraghavan, Rengasayee; Mezache, Louisa
  • Licensing Officer: Willson, Christopher

Gene Therapy Compositions for Treating Cardiovascular Diseases
TS-063091 — A gene therapy approach to address the specific needs of failing hearts.
Heart failure affects over 6 million adults in the US and can lead to irreversible damage to the heart. The Need In the realm of cardiovascular health and the management of heart-related disorders, there exists a pressing commercial need for a technology that can effectively address the challenge…
  • College: College of Medicine (COM)
  • Inventors: Lewandowski, E. Douglas; Carley, Andrew
  • Licensing Officer: Willson, Christopher

Dual-payload Humanized Antibody-Drug Conjugate (DualADC) for targeted chemo-immunotherapy
TS-062822 — Dual payload ADC chemo-immunotherapy and Humanized mAb for cancer treatment
The Liu Lab Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene ther…
  • College: College of Engineering (COE)
  • Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
  • Licensing Officer: Schworer, Adam

A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
  • College: College of Medicine (COM)
  • Inventors: Tedeschi, Andrea
  • Licensing Officer: Willson, Christopher

Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males. The Need Despite the crucial role of androgen receptors (AR) in HCC progress…
  • College: College of Pharmacy
  • Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
  • Licensing Officer: Willson, Christopher

Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
  • College: College of Medicine (COM)
  • Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
  • Licensing Officer: Bhatti, Hamid

Show More Technologies

Loading icon